Tradjenta, 12.) Xifaxan, 13.) Vraylar, 14.) Janumet, Janumet XR, and 15.) Otezla. Considine criticized corporate drug ...

The FDA Wednesday approved the first drug to treat people with Prader-Willi syndrome, a rare genetic disease that causes an ...

Since 2000, when the FDA approved recombinant human growth hormone (rhGH) for those with the rare genetic disorder ...

First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome. Management to host conference call and webcast today, March 26 th, at 5:30pm ET. REDWOOD C ...

Shares of Soleno Therapeutics jumped 40% in morning trading on Thursday, after the company's drug for a rare metabolic condition became the first such treatment to receive U.S. regulatory nod.

Soleno on Wednesday said the FDA approved its Vykat XR extended-release tablets for the treatment of hyperphagia, a chronic and life-threatening feeling of intense, persistent hunger, in people ages 4 ...

Danish drugmaker Novo Nordisk is prepared to enter the Indian market and other markets with its blockbuster drug Ozempic, despite losing patent exclusivity early next year. “Even as we face ...

The federal government is looking to reduce the cost of certain medications. There is currently a major “price negotiation” underway. A few thoughts: Everyone is talking about or using weight ...

Drugmaker Hikma is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents on Novo Nordisk’s blockbuster diabetes and weight loss drugs ...

Soleno Therapeutics (SLNO) “announced that the FDA has approved VYKAT XR, diazoxide choline, extended-release tablets, previously referred to ...